Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Immuvent AB
AB
Active
Org 5567522189
Sysslomansgatan 47 F, 752 27
Uppsala
General medical practice activities
·
NACE 8621
Est. 2008 · 18 years old
0 employees
Overvåg
Share
Sweden
/
Companies
/
General medical practice activities
/
Immuvent AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
0
0
0
0
0
Staff expenses
—
—
—
—
—
EBITDA
−53
−25
−27
−26
−18
Depreciation & amort.
−0
—
—
—
—
EBIT
−53
−25
−27
−26
−18
Net financials
−558
148
55
−1 653
−15
Profit before tax
381
123
28
−1 678
−33
Tax
−0
—
—
−38
—
Net profit
381
123
28
−1 716
−33
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
2 669
2 452
2 285
411
365
Equity
2 661
2 443
2 280
368
335
Long-term debt
0
—
—
—
—
Short-term debt
8
8
5
43
30
Total debt
8
8
5
43
30
Financial ratios
5-year trend
EBITDA-margin
-1799600.0%
This company
15.8%
Market median
-11389973% vs market
2021
2025
Soliditetsgrad
91.8%
This company
38.2%
Market median
+140% vs market
2021
2025
Egenkapitalforrentning
-9.9%
This company
18.4%
Market median
-154% vs market
2021
2025
Nettoresultatgrad
-3310800.0%
This company
8.1%
Market median
-40874174% vs market
2021
2025
Aktivomsætning
0.00×
This company
1.12×
Market median
-100% vs market
2021
2025
Gæld/egenkapital
0.09×
This company
0.62×
Market median
+85% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
View
PDF
More on Immuvent AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
